Loading...
Market
What will be the price range of Lenacapavir in its first year of launch?
2
Resolution / Starting Odds
Below $10,000 per year • 25%
$10,000 - $20,000 per year • 25%
$20,000 - $30,000 per year • 25%
Above $30,000 per year • 25%
Official pricing information from Gilead Sciences or pharmaceutical pricing databases
Story
Gilead's Lenacapavir Cuts HIV Infections by 96% in Phase 3 Trial, Boosting Stock
Sep 12, 2024, 01:32 PM
Gilead Sciences announced that its twice-yearly HIV prevention drug, Lenacapavir, has demonstrated a 96% reduction in HIV infections in its second pivotal Phase 3 trial, PURPOSE 2. The trial included men, transgender women, and non-binary individuals, following a previous trial in cisgender women. Lenacapavir showed superiority to daily Truvada, with only two infections among 2,180 participants, representing 99.9% effectiveness. As a result, Gilead has stopped the blinded phase of the trial and will offer Lenacapavir to all participants. The success of this trial positions Gilead to file for regulatory approval by the end of the year, potentially leading to a 2025 launch. However, there are concerns about the high cost of the drug, which may impact its accessibility. The announcement has boosted Gilead's stock, sending shares higher.
View original story
Similar markets
Less than $50 annually • 25%
$50 to $100 annually • 25%
$100 to $500 annually • 25%
More than $500 annually • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Uniform pricing across all markets • 25%
Tiered pricing based on market income levels • 25%
Significant discounts in low-income countries • 25%
Other pricing strategy • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
Dr. Reddy's Laboratories • 25%
Cipla • 25%
Mylan • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%